Greetings. Welcome to the Viemed Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I'll now turn the conference over to your host, Todd Zehnder. You may begin. Thank you. Good morning, everyone. Please note that our remarks in this conference call may include forward-looking statements under the US Federal Securities laws or forward-looking information under applicable Canadian securities legislation, which we collectively refer to as "forward-looking statements." Such statements reflect the company's current views and intentions with respect to future results or events and are subject to certain risks and uncertainties, which could cause actual results or events to vary from those indicated in the forward-looking statements. Examples of such risks and uncertainties are discussed in our disclosure documents filed with the SEC or the securities regulatory authorities in certain provinces of Canada. Because of these risks and uncertainties, investors should not place undue reliance on forward-looking statements. The forward-looking statements made in this conference call are made as of today, and the company undertakes no obligation to update or revise any forward-looking statements as required by law. The third quarter financial results news release, including the related financial statements, are available on the SEC's website. I'll now turn it over to Cas ey to get things started. Okay. Thank you, Todd. Good morning, everyone, and thank you for joining our third quarter earnings call. Today, I'll be providing commentary on our positive operational results this third quarter, as well as our current view and outlook of the industry. I'd like to begin, as always, by acknowledging and thanking our dedicated team of respiratory therapists, behavioral health specialists, staffing professionals, and administrative support staff who work tirelessly to deliver the best-in-class care to our patients. We are privileged to have these employees within the communities that we serve, as they pride themselves with their servant mentality. As of September, our Viemed family grew to 722 employees. Underlying these numbers is a substantial increase in sales hiring, offset by natural turnover in administrativ e functions. Our rate of hiring for sales positions is at an all-time high, thanks to the support of our VHS staffing division. Through September, we have hired 52% sales reps and converted four existing employees to sales reps. We're also seeing positive retention trends with our existing sales force, contributing to an overall 34% net growth in sales force compared to the beginning of the year. In the third quarter, we added eight new geographic areas, bringing our net new areas for the year up to 23, which puts us in position to certify our goal of adding on 25 new areas by the end of the year. Based on the historic productivity curve of new hires in our sales force, we are optimistic about the robust organic growth potential coming through the pipeline over the next six to 12 months, strengthening our 2023 growth optimism. In addition to investing in growth and with the help of our maturing digital process improvement investments, we were able to reverse margin compression associated with the increased labor and inflation costs. Our competitive advantage and organizational value comes from our ability to leverage the best available technology combined with the best people. Technology, like our proprietary digital health platform, Engage, has enabled us to monitor our patients in greater volumes, reduce overhead, and continue to treat patients in a way so that their needs can be met efficiently and effectively. With over half of our vent patients now on the Engage connected health platform, we are able to leverage data and the division of labor that comes with our scale. e-prescribing and e-ordering platforms that we offer are also being rapidly adopted by providers, patients, and payers, further contributing to our efficiencies. These platforms reduce on paperwork and time, creating a more timely and frictionless patient and provider experience. We've also recently completed a refresh of our website with an emphasis on the digital patient experience. A new digital ordering page and educational resource center, complete with patient tutorial videos, is now available on the web. In addition to the innovative business approach through the use of technology, we are also innovating our approach to clinical services. Through our behavioral health division, Viemed Clinical Services, we are able to provide targeted clinical responses to patients requiring specialized mental and environmental care for our referral sources. The combination of our Engage technology, coupled with human touch supported by behavioral health, is generating improved compliance, which is leading to improved levels of care, driving patient longevity. Our high-touch, high-tech approach also continues to open doors and make Viemed an attractive partner to large institutional providers like the VA and regional hospital networks. We are in various stages of partnership development with a number of large healthcare institutions, including a recent engagement with the VA during the third quarter. We have been awarded a solicitation contract to place our people in the homes of veterans in need of pulmonary disease management, social services, and behavioral health. The VA has asked us to track the patient results using our Engage platform and share the results on clinical outcomes and patient satisfaction. I'm very excited about this opportunity to work with the VA on this project, which has the potential to dramatically improve the lives of veterans living with COPD on a widespread national level. Value-based and at-risk administrators are seeking specialty care solutions, and Viemed's health tech offerings are solving the problems that major networks are facing within large COPD populations. During the third quarter, a study authored by our Chief Medical Officer was published in Respiratory Medicine, a peer-reviewed medical journal. The study is being regarded as groundbreaking in the industry for the first of its kind findings related to the overall healthcare cost savings. Using the largest data set to date, this study also reaffirmed that the sooner CRF patients initiated non-invasive ventilation treatment, the greater the mortality and hospital readmission improvements. In addition to the academic presentations of findings by Dr. Frazier, our sales reps have been actively discussing the study with our referral network of prescribing physicians. Concurrently, our payer development team has been vigorously engaged with commercial payers among our network to ensure that the right patients are getting the right care in a timely, effective, and cost-efficient manner. Despite signs that the overall economy may weaken in upcoming periods, our operating environment is actually stabilizing and showing signs of significant improvement. As a respiratory-focused healthcare company, we face unique and significant challenges during and after the pandemic. Labor and supply chain constraints led to increased costs and shortages across the industry. Today, labor markets are stabilizing, and a number of new manufacturers have entered the supply chain and are delivering equipment at lower cost than ever before. The OIG review is closer to complete resolution, with nearly all of the original findings overturned. Our access to physicians and referral sources are now restored, with clinics seeking innovative ways to free up beds by sending patients home with our equipment and services. Reimbursement rates for Medicare and most commercial plans are expected to rise during 2023 as a result of established inflation adjustments. When considering the positive trends in patient growth, reimbursement rate increases, and supply chain improvement, we are very excited about the future potential for our organizational growth and the creation of shareholder value in the year ahead. During the quarter, we spent a significant amount of time working through our processes to onboard potential acquired companies with our executive leaders and departments. Our new M&A team is extremely active and supportive of our disciplined approach with our current pipeline of targets. With that said, we're excited and expect to supplement our growth with acquisitions in the coming quarters. We also continue to execute on our share repurchase program while at attractive valuation levels. Our organic growth in non-vent product and service lines continues to add opportunity and diversification to our business. Our sleep business is setting records for new patient setups, which has pushed our more profitable resupply revenue stream into greater numbers. Our oxygen business is also growing at a rapid pace, which allows us to fully support the patient's care journey across all stages of their progressive respiratory disease. In addition to supporting Viemed's internal staffing needs, our staffing division is exceeding revenue and profitability expectations for the external staffing services it provides to hospital and government agencies. Although we are growing ventilator patient count at the highest rate since before the pandemic, our non-ventilator revenue growth continues to perform better than expected. The result is that we are successfully adding diversity to our portfolio mix, ending the quarter with 33% of our revenue derived from non-vent resources. In addition to the strong revenue growth of our existing service lines, we are continuously developing new services and programs to address the needs of an evolving healthcare market and the growth of Viemed. With more on our operations, financials, the buyback and the regulatory landscape, I'll now turn the call over to our Chief Operating Officer, Todd Zehnder. All right, thank you, Casey. In reviewing the financial results, all figures are in US dollars, and the full results have been made available on the SEC website as well as SEDAR. Our core business generated net revenue of $35.8 million during the quarter, third quarter, as compared to net revenues of $27.8 million in the third quarter of 2021, which equates to a 29% increase. Our sequential growth for the core business was 8%. As indicated last quarter, we are now back to seeing growth across all of our major product lines and have very little restrictions to our access around the country. Our gross and EBITDA margin percentages are once again very healthy and are now back to being just from our core business lines. As indicated last quarter, we anticipated our margins to begin to turn around towards the end of the year or next year, and we're pleased that we were able to show a slight increase in EBITDA margins sequentially. We continue to see our margin profile be influenced by our product mix and continue to be pleased by the notional growth. Our gross and EBITDA margins during the quarter came in at 61% and 20% respectively. Our third quarter gross and EBITDA amounts came in at $21.7 million and $7 million respectively. Our third quarter revenue from vents was approximately 67% of our core, as compared to 78% in the third quarter of 2021. We saw our active patients grow across all product lines and now have four products that we are comfortable saying are rolled out across a significant portion of the country. We should continue to see economies of scale as we continue to grow these lines. Our SG&A for the quarter totaled approximately $17.7 million, as compared to $13.3 million in the third quarter of 2021, and is flat with the prior quarter. As indicated last quarter, we have ramped up hiring to serve our growing patient panels around the country and expand our organic growth model in new areas. We did front load many of our significant hiring initiatives as evidenced by a flat G&A quarter, but we continue to pursue talent to help with our ongoing growth initiatives. Following on our last quarter comments, we have managed the inflationary effect that we are seeing in our business but doing so in the spirit of not sacrificing patient growth or bottom-line growth. For the quarter, we invested approximately $6.3 million on capital expenditures. The CapEx continues to be spent across all of our major product lines as we have continued to grow all products and manage this through a diversified supplier network. As we have managed through the Philips recall, we are happy that we have maintained adequate supplies to service our growing patient base. We will continue to diligently monitor supply chain issues in the future in order to maintain adequate inventory levels. We once again funded all of our CapEx with discretionary cash flow during a quarter where organic patient growth is as high as we have seen in a couple of years. We continue to have a pristine balance sheet, where at September thirtieth we had a cash balance of $21.5 million and an overall working capital of $22.3 million. Our total long-term debt stands at $4.2 million. We have continued to opportunistically capitalize on our previously announced stock buyback. During the third quarter, we bought back 323,053 shares for total expenditures of approximately $1.9 million. As of 30 September 2022, we had purchased approximately 1.67 million shares out of the total available, approximately 2 million shares under the plan. We are pleased that we've been able to execute on our organic growth strategy as well as our stock buyback, all while remaining an extremely low leverage company. Historically, organic growth and the buyback took precedent from a capital allocation standpoint. Now that our M&A team is building out a pipeline of opportunities, we are confident that we have a third leg of the stool to add shareholder value. We believe there will be ample opportunities to capture inorganic growth in the coming years. Moving on to the ongoing OIG and CMS issue related to our NIV claims. We are down to eight patients that have been deemed ineligible for several factors, and the company is having a hearing at the ALJ this week. We are hopeful that this will be the last phase of the appeal, and we anticipate having a successful outcome during this process. The company paid the $1.1 million that is still being debated, and it was recorded as a prepaid asset. We are hopeful to have the outcome of the ALJ hearing before year-end. Moving on to the fourth quarter. We have provided net revenue guidance in the $37.1 to 38.1 million range related to our core business. Our core revenue is guided up 30% to 31% over the fourth quarter of 2021. At this time, I'd like to turn the call back to Casey to wrap it up. Thank you, Todd. I'm extremely proud of how our team executed in the third quarter. We have successfully reversed an EBITDA margin compression trend through the efforts of creating operational efficiencies through our investment into good people and good technology. We are also well positioned in this current and forward-looking economic environment. While most are experiencing a labor shortage, our investment into staffing has allowed us to not only elude this challenge but flip it into an opportunity that is generating growth for our company. The ability to provide staffing solutions to our referral sources is putting us into a wonderful position to execute on strategic hospital partnerships that go into the home. We continue to thrive in this fee-for-service world, but this has not changed our relentless pursuit nor our view of value-based arrangements being the future of reimbursement for our industry. Trends in the current regulatory landscape continue to reaffirm the value of home-based healthcare. The organic business model is back to growing at impressive rates, and we have the team and structure in place to expand the model further with an underserved population of patients in need. While we have not yet completed an acquisition, we see M&A as a major prong of our future growth model going forward. We recognize there are challenges in the country but remain excited about the near term and long term of our business. History has shown where others perceive headwinds, Viemed sees tailwinds. We love to be opportunistic during challenging times, and this often leads us to being on the forefront of technology and clinical solutions for our payers, referral sources, and ultimately our patients. We want to thank all of our investors for their continued trust in our company and look forward to driving further shareholder value. This concludes our prepared remarks. I want to thank everyone for taking time to join our call today and look forward to answering further questions. At this time, we will be conducting a question-and-answer session. If you'd like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. Our first question comes from the line of Brooks O'Neil with Lake Street Capital Markets. Please proceed with your question. Thank you. Good morning, guys. Terrific quarter, and frankly, a terrific review of all the many things you have going on. I appreciate that very much. Thanks, Brooks. Thank you, Brooks. Yep, I have a couple questions. I heard you mention reimbursement, and I think the primary change relates to an inflation adjustment, but have there been any underlying sort of changes in the fundamental reimbursement structure in the areas you guys are focused on? No, we have not heard of anything. Right now, we are anticipating just whatever comes out through inflationary, you know, mainly driven by the CPI. Yep. Okay, great. You talk about the acquisition opportunity, which I personally believe is huge. I'm just curious if you think the most likely scenario is to kind of be opportunistic about trying to expand your core business operations, or is it more likely you might view an acquisition in a technology area or something like that? More likely to expand our core business. We are looking at other ways to expand our technology business as well. I would say, Brooks, a way to answer that question might be that 80% of the pipeline is really related to growing the core business and the other 20% might be more strategic with technology. Okay, that's helpful. Appreciate that, Casey. One area I'm curious about is I actually spend quite a bit of my time on an area that I call remote patient monitoring, and I know you guys are involved in this area, but my sense is that there's a growing number of reimbursement codes that doctors can utilize to be paid to monitor patients remotely. Candidly, my sense is there isn't a doctor in America that has that capability inherently in his practice, his or her. I sense that there's a growing opportunity for technology and service providers to support doctors and help them to collect that reimbursement. Is that something, A, you see in the areas you focus on and/or B, is it an area that has any appeal for you guys in respiratory care? Yeah, that's how we started, Brooks, with the rollout of our RPM devices, was going straight to the doctors and presenting it in a way where they could make some additional revenue streams and keep a better clinical watch on their patients from afar. However, I'm seeing the trend more leaning toward RPM going towards directly to the payer and to the hospital systems, and as it relates to the hospital systems, they're faced with a labor shortage, and they're trying to fill up their beds, but they don't have the clinicians to really support that. They're looking for ways of treating more patients in the home, and then that's got them keeping their eye on the ball on remote devices that might be helpful in that hospital-to-home type of program, so... [crosstalk] Mm-hmm. The bigger fish. That's the bigger fish or the bigger win, if you will, is with those payer groups and those hospital systems that want to embrace it. Yes, the physician who wants to make a little bit more money is certainly gonna do so, but it won't drive the volumes that the hospital systems and payers can bring. Okay. That makes total sense to me. I appreciate that commentary, Casey. The last thing, obviously, you've been very successful with the stock buyback. Sounded to me like you're kind of getting towards the tail end of your current authorization. I'm curious if you've had any conversations with the board or given any thought to expanding the authorization or renewing it once you get to the 2 million shares. Yeah, we haven't had any preliminary discussions on that, Brooks. We're gonna, you know, be patient and finish this one off in due time. Now that we have the M&A team, we're also mindful that keeping some dry powder ready to go deploy in some sort of acquisition is another good use of the capital. Until we get there, we haven't made any decisions, though. Totally get it. Thanks a lot. Great quarter. Great job, you guys. Thank you very much for taking my questions. Thanks, Brooks. Our next question comes from the line of Doug Cooper with Beacon Securities. Please proceed with your question. Hey, good morning, guys. Casey, I just wanted to confirm that I heard you right. You've hired 52% sales reps' year to date. Is that what you said? Yes, that's correct. Okay. How many... [crosstalk] reps do that bring us to total? Sorry, Doug... [crosstalk] we have 52% sales rep. We have added another 4%. That's roughly 56% new sales reps. Go ahead with your question. How many do you have in total now? Ooh, 90%, almost a 100%. We're just shy of a 100%. Okay. How long does it take an average sales guy to ramp up to full productivity? It varies, but we usually give them six months, and that's something that is all over the map. Very hard to put your finger on. We got folks that start really fast and then some that take the full six months to ramp up, but end up being in our top 10% of sales reps. We pay very close attention to that, and we give folks a lot of training and support and rope to give them the opportunity to be successful. Yeah, it's a hard question to answer. Okay. I guess I'm just trying to get at when everybody's full productivity, what does that mean for a sales guy in terms of an annualized target for revenue per salesperson? Annualized target for revenue per sales. I get... [crosstalk] We don't really track that. If you had... [crosstalk] 100% sales guys. Yeah, if you had 100% sales guys today and you started the year at about or ended the last year around 44%, I guess, right? No, we've had turnover included in those numbers, Doug. Okay. I guess I'm just trying to get at, you know, when these guys, you know, that's a bunch of new sales guys when they ramp up, like how incremental should the revenue increase? [crosstalk] I'd rather you pay more attention to the net new areas, which is what I commented on. This is one of the first quarters where I just wanted to give you all some color on how many reps it took to get to the 23% net new areas. That's really the 23%, you know, incremental businesses that we've added on this year, business areas that we've added on. Okay... [crosstalk] Does that make sense? What percentage increase is that... [crosstalk]? We set a goal at the beginning of the year to get to 25%, and we're sitting at 23% at the end of the third quarter. We're gonna be ahead of that goal, that year-end goal. Okay. That 23% would represent a year-over-year increase in of what, for example? Of another area where we set up a sales rep that's oftentimes supported by another type of assistant sales rep that could have maybe two or three respiratory therapists underneath them. There's a lot going on there, but it's the best way to think about how Viemed is expanding. We've gone 60 miles down the road, and we have set up a new area. Rather than buying a business, we have incrementally added on to our organic engine by setting up that new area. Does that make sense? Yeah, yeah. No, I get that. I'm just wondering, like, if as a percentage of increase, the 23% net new areas represent, is that 20% year-over-year growth in areas or what? It's a 34% growth number. 34%. Okay. On your wish list, when I look forward 12 months from now, how many net new areas would you want to add this time next year? How many are capable of adding given the resources you have? I'm assuming, you know, the M&A will also augment that growth into new areas, I'm guessing. We haven't set that number yet, but, I mean, you can figure as we always like to be growing around that 30% number or setting our goals in that area, if you will, when we're working with our team for the organic piece of the business. Just figure in another 30% something jump. Okay. Todd, just on the phantom shares, the impact on D&A this quarter was $450,000. That's real dollars? Just remind me how that works and it's reflective of the increase in stock price? That's a real expense, but it's settled in cash once a year, Doug. That's just a mark to market of those plans, which, you know, as we've signaled to the market, is definitely going down over time... [crosstalk] Mm. Because it is settled in cash, whereas the restricted units that we use, that go through the stock-based compensation are settled in stock, you actually have a mark to market component. Okay. My final one, I noticed that bad debt as a percentage of revenue dropped. I think it was 4.1% in the quarter, down from 8% in last quarter. Pretty low. Any comments on that? Yeah. I think we've gotten a little more sophisticated on the reserving earlier in the year, where it may be a little bit more difficult to collect. You know, we were a little higher in the first and second quarter than we want to be. I would just say that we want to keep that number in the 6% to 8% range on an annualized basis over time and are hoping to... [crosstalk] Mm-hmm. You know, hoping to drive it down. It's, as collections have gotten stronger and, you know, everything is just getting more systematic. I would hope to drive that down every year. Okay. Oh, just on the CPI adjustment, is that my understanding it'd be around 5%? Is that sort of in the ballpark of what you're thinking? If we look at historical data, what the CMS typically uses is the June CPI, which came in at 9.1%, and then there's a productivity adjustment made. If we are able to use historical averages, it would be in the upper 8%. We won't know that number probably until late November or early December. That'll give effect 1 January 2023. That's correct. Okay. What do you think the commercial payers will do? That's what Medicare will increase. Will the commercial payers increase as well? Or just be on the Medicare side of the business? That really just comes down to individual negotiations or discussions. Some of our contracts are tied to Medicare rates, so those would just get a pass-through immediately. On the ones where you have fixed fee schedules, it just takes our network development team getting back on the phone and hoping for some sort of inflationary relief. Okay. That's great. Thanks, guys. Great quarter. All right, Doug. Thanks. Thank you. As a reminder, if anyone has any questions, you may press star one on your telephone keypad to join the question-and-answer queue. Our next question comes from the line of Prasad [inaudible] with Bloomberg. Please proceed with your question. Hi. Good morning. Thanks for taking my questions. First, on the SG&A expenses, which is about $17.7 million this quarter, how are these split between kind of the fixed component, which is the operating leverage, and the variable component, which kind of goes up and down with the top line? I would say the majority of our SG&A is somewhat fixed. When I say majority, probably at least three-quarters. The biggest component of that is the wages for everybody that's not touching patients, so roughly 500 or so employees. Commissions, things like fuel, things like bonus programs and so forth, those are variable. That probably makes up 20% to 25%. Okay, that's useful. You expect this split to be, like, stable going forward? I would, yeah. Those numbers have stayed relatively flat. We would hope that we can drive down SG&A as a percentage of revenue over time. Okay. As we create more operating leverage. I would expect the components between fixed and variable to stay somewhat consistent. Okay. Got it. Then on the M&A strategy, you know, given the significant changes in the broader economy and financial markets, are there any changes to your kind of, the areas that you target and the companies and the multiples you'd be willing to pay for these companies? Yes. I mean, some of these companies have been in our pipeline for two years and are coming back around to us with a reset of multiples in the market, if you will. That's a positive for our guys who are out there having the conversations right now. I just think the other part to that is the components of any financing. Now you have to consider a higher leverage rate and so forth. I think that will inherently bring down multiples just cause the cost of capital is going up as well. Okay. Yeah, that makes sense. Just to confirm, the CPI adjustment, your baseline expectation is in the 8% range for next year? That's our expectations, Prasad. You know, we're obviously gonna wait for CMS to come out with the number. If we use historical context, then that should be where they come in. Great. All right. Yeah, that's useful. Thank you very much. Thanks. Our next question comes from the line of Nick Corcoran with Acumen Capital. Please proceed with your question. Good morning and congrats on the record quarter. Thanks, bud. Thanks, Nick. Most of my questions have already been asked. I guess my first or my only question is, you added 23 areas in the kinda year to date. How long does it take for an area to fully mature? Again, it's kinda going back to Doug's question. It really revolves around the rep's development. All areas are different. It depends on how seasoned the rep is, what their historical sales experience and contacts have been. Those typically will start up a little bit faster than the ones who's starting without contacts. We've had both end up in the top 10% of successful reps in areas, so it's all over the map. It's hard to answer. If we think of your your maybe like 75 areas, I guess there's a range of organic growth just depending on the maturity of the area. Is that a fair assumption? Yes. On an area-by-area basis? Yeah, exactly. Yeah. Oh, absolutely. If you have a relatively newer area that, let's just say, they became established in the first quarter of this year and started having an impact, their organic growth rates are gonna be much higher than, say, an area that's been around for seven or eight years, just 'cause the more established area has attrition of, you know, just the 17-month length of stay, you're losing patients. From a gross new patient adds, those are some of the most important areas, which is your larger areas. If you're just looking at it on a percentage basis, relatively immature, successful areas are gonna drive the most percentage bang. Okay. Thanks. That's all for me. All right, Nick. Thanks. We have reached the end of the question-and-answer session. I'll now turn the call back over to Casey Hoyt for closing remarks. Okay. Thanks for everyone joining our call today. We appreciate it. We're getting back to business. Have a good one. This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation.